

Application no. 09/911,703

Attorney Docket no. 27693-01008

*en*  
*1644/1B*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.: **09/911,703**  
Confirmation No.: 4927  
Filed: 25 July 2001  
Applicant: Darrell R. ANDERSON et al.  
For: Anti-CD20 Antibodies

Group Art Unit: 1644  
Examiner: R. Schwadron

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the documents listed on the Form PTO-1449 that accompanies this paper. Applicant does not represent that a search has been conducted or that the cited documents, copies of which are submitted with this paper, are prior art against the claims in this application.

Applicant also directs the examiner's attention to the commonly owned, pending U.S. patent applications listed below.

Serial No.	Filing Date	First Inventor
09/783,038	15 Feb 2001	Anderson
09/911,692	25 Jul 2001	Anderson
09/911,703	25 Jul 2001	Anderson
10/096,964	14 Mar 2002	Anderson
10/238,681	11 Sep 2002	Anderson
10/956,039	04 Oct 2004	Anderson

10/04/2005 HALI11 00000004 181260 09911703  
01 FC:1806 180.00 DA

This disclosure statement is filed before the mailing date of a final Office action under the provisions of 37 C.F.R. § 1.97(c)(2). As indicated on the fee transmittal that accompanies this submission, the Director is requested to charge the requisite fee (\$180), as well as any other fees that may be required to make this submission timely or proper, to our Deposit Account No. 18-1260.

Respectfully submitted,



David L. Fitzgerald, Reg. No. 47,347  
Attorney for Biogen Idec Inc.


SIDLEY AUSTIN BROWN & WOOD LLP  
1501 K Street, N.W.  
Washington, DC 20005

tel. (202) 736-8818

fax (202) 736-8711

Date: 30 September 2005

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Docket No.</b> 27693-1008	<b>Application No.</b> 09/911,703
	<b>Applicant(s):</b> ANDERSON, Darrell R.	<b>Examiner:</b> SCHWADRON, Ronald B.
	<b>Filing Date:</b> 7/25/2001	<b>Group Art Unit:</b> 1644



### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	A1	4,975,278	12/4/1990	Senter et al.			
	A2	5,677,180	10/14/1997	Robinson et al.			
	A3	5,686,072	11/11/1997	Uhr et al.			
	A4	5,693,780	12/2/1997	Newman et al.			
	A5	5,721,108	2/24/1998	Robinson et al.			
	A6	5,843,398	12/1/1998	Kaminski et al.			
	A7	6,015,542	1/18/2000	Kaminski et al.			
	A8	6,090,365	7/18 /2000	Kaminski et al.			
	A9	6,120,767	9/19/2000	Robinson et al.			
	A10	6,287,537	9/11/2001	Kaminski et al.			
	A11	6,565,827	5/20/2003	Kaminski et al.			
	A12	6,652,852	11/25/2003	Robinson et al.			
	A13	6,893,625	5/17/2005	Robinson et al.			
	A14	2002-0009444	1/24/2002	Grillo-Lopez			
	A15	2003-0021781	1/30/2003	Anderson et al.			
	A16	2003-0026804	2/24/2003	Grillo-Lopez			
	A17	2003-0082172	5/1/2003	Anderson et al.			
	A18	2003-0095963	5/22/2003	Anderson et al.			
	A19	2003-0147885	8/7/2005	Anderson et al.			
	A20	2003-0206903	11/6/2003	Grillo-Lopez			
	A21	2004-0213784	10/28/2004	Grilo-Lopez et al.			
	A22	2005-0163708	7/28/2005	Robinson et al.			
	A23	2005-0186205	8/25/2005	Anderson et al.			

### FOREIGN PATENT DOCUMENTS


	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A24	WO 91/04320	4/4/1991	WO				X
	A25	WO 93/02108	2/4/1993	WO				X

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A26	Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with <sup>131</sup> I-labeled Anti-T-Cell Antibodies." Cancer Research, 46, pp. 6223-6228, 1986.
	A27	Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." Cancer Research; 52, pp. 637-642, 1992.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
<b>Form PTO-A820 (also form PTO-1449)</b>	


<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Docket No.</b> 27693-1008	<b>Application No.</b> 09/911,703
	<b>Applicant(s):</b> ANDERSON, Darrell R.	<b>Examiner:</b> SCHWADRON, Ronald B.
	<b>Filing Date:</b> 7/25/2001	<b>Group Art Unit:</b> 1644



**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

A28	Biogen Idec v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. California, January 22, 2004).
A29	Chen, et al. "Tumor Idiotypic Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
A30	Clark et al Role of the BP35 cell surface polypeptide in human B-cell activation, Immunology Vol. 82, pp. 1766-1770, 1985.
A31	Clark et al. "Phase I of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." Journal Cellular Biochemistry Supp. 9A, p. 63, 1985
A32	DeNardo, et al. "Fractionated Radioimmunotherapy of B-cell Malignancies with <sup>131</sup> I-Lym-1." Cancer Research (Suppl.) 50, pp. 1014s-1016s, 1990.
A33	Idec Pharmaceuticals v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 486,584] (S.D. California, October 14, 2003).
A34	Kaminski, et al. "Initial Clinical Radioimmunotherapy Results with <sup>131</sup> I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." Antibody Immunoconjugates, and Radiopharmaceuticals Vol. 5, No. 3 p. 345, 1992.
A35	Kaminski, et al. "131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
A36	Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine Biology Vol. 19, No. 2, pp. 213-225, 1992.
A37	Levy, et al. "Tumor Therapy with Monoclonal Antibodies." Federation Proceedings 42:9 pp. 2650-2656, 1983
A38	Macklis, et al. "Radiobiologic Studies of Low-Dose-Rate <sup>90</sup> Y-Lymphoma Therapy." Cancer Supplement, Vol. 73, No. 3, pp. 966-973, 1994.
A39	Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody mAb) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." Interferon and Chronic Myelogenous Leukemia." Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
<b>Form PTO-A820 (also form PTO-1449)</b>	



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Docket No.</b> 27693-1008	<b>Application No.</b> 09/911,703
	<b>Applicant(s):</b> ANDERSON, Darrell R.	<b>Examiner:</b> SCHWADRON, Ronald B.
	<b>Filing Date:</b> 7/25/2001	<b>Group Art Unit:</b> 1644

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

A40	Maloney, et al. "Monoclonal Anti-Idiotypic Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotypic-Negative Variant Cells." Blood, Vol. 80, No. 6, pp. 1502-1510, 1992.
A41	Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." Medical Oncology Tumor Pharmacother Vol. 8, No. 3, pp. 207-220, 1991.
A42	Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." Journal of Clinical Investigation, Vol. 67, pp. 134-140, 1981.
A43	Reilly, "Radioimmunotherapy of malignancies." Clinical Pharmacy, Vol. 10, pp. 359-375, 1991.
A44	Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.
A45	See-Lasley, et al. "HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981.
A46	Senter, et al. "Enhancement of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." Cancer Research 49, pp. 5789-5792, 1989.
A47	Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." The Journal of Immunology Vol. 125, No. 4, pp. 1678-1685, 1960.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
<b>Form PTO-A820 (also form PTO-1449)</b>	<b>SHEET 3 OF 3</b>